Following global reports of serious adverse events in older people, the government’s independent expert advisory body, the UK ...

UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines, confirming a ...

The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...

A "sub-study" of a late-stage clinical trial found the drug, obicetrapib, significantly reduced levels of a certain type of ...

The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...

The latest update atopic dermatitis guidelines include the new approval of lebrikizumab and the expanded use of baricitinib ...

EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...

The purpose of the pharma package is to revise the current rules on medicines to make them more accessible to patients while ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple myeloma.

The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.